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Pathophysiological Implications
Magnus Sjögren, Stein Frostad  
and Kenneth Klingenberg Barfod
Abstract
Anorexia nervosa (AN) is a severe and often enduring condition of which the 
etiology is unknown. Studies on the gut microbiota in AN have found deviations 
from that of healthy individuals, which may imply a relation to pathophysiology, 
development and maintenance of the disorder via the gut-brain axis, which has 
been shown in other disorders. A narrative review of the gut microbiota studies in 
AN is presented. Several studies point to a dysbiosis in AN which may have implica-
tions for maintenance of a low body weight, immunological changes and a severely 
reduced food intake. An association may be found to clinical symptoms in AN. A 
pathophysiological model for disease is presented implying a role of the microbiota 
in maintenance of AN. Dysbiosis in AN may play an important role in the develop-
ment and maintenance of AN.
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1. Introduction
Anorexia nervosa (AN) is a serious and often enduring psychiatric condition. 
The hallmark features of AN are a phobia for weight gain, and for intake of fatten-
ing food, disturbance in body image, and often compensatory behaviors such as 
excessive exercise and purging, which overall leads to a reduction of energy intake 
relative to energy expenditure leading to low body weight. An increased risk of sui-
cide and frequent potential life-threatening medical complications of several body 
organs contribute to AN having a high standardized mortality ratio of 5.2 [3.7–7.5] 
[1]. This is coupled with a high risk of enduring disease [2].
The weight loss is in some patients preceded by a depression, a trauma, gas-
trointestinal symptoms or an infection. But in a majority of patients there is no 
detectable psychiatric or somatic disorder preceding the weight loss. In children and 
adolescents with AN, family-based treatment as described by Lock and LeGrange is 
recommended [3] and if treatment is started shortly after debut of the disorder, the 
prognosis is fairly good. However, if treatment is delayed, the prognosis becomes 
worse [4]. In adults, individual eating-disorder-focused therapy (CBT-ED) is rec-
ommended [5]. With this treatment, drop-out rates are high and even with optimal 
treatment by well-trained therapists only 50% of the patients who start CBT-ED 
have good effect of the therapy [6, 7].
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Considering the high mortality, high chronicity and lack of knowledge on the 
etiology of AN, there is an immense need for an improved understanding of the 
etiology and pathophysiology of the disease in order to find ways to better treat-
ments. This knowledge would preferably explain both the routes into developing 
the disorder and mechanisms that serve to maintain it, and proposedly involve both 
biological and psychological factors, such that measures and biomarkers to follow 
the development and recovery from of the disease could be identified. Potential 
further benefits with biomarkers for AN may be guidance for risk stratification, 
treatment and target identification for novel treatments. The last few years have 
seen an increase in studies on the gut microbiota and its associated microbiome 
which might harbor trait biomarkers for AN.
The “microbiota” refers to the cumulative microorganisms, including Bacteria, 
Viruses, Archaea, Protists and Fungi, which populate a number of human tissues 
and biofluids including the skin, lungs, roal mucosa, saliva, and gastrointestinal 
tract, and the “microbiome” refers to the collective genomes of the present micro-
organisms [8]. There are more than 1000 ‘species-level’ phylotypes that coexist in a 
human [9], and the majority of these phylotypes are Bacteria, with Faecalibacterium 
prausnitzii, Roseburia intestinalis, and Bacteroides uniformis dominating in the 
adult microbiota found in feces samples [10]. The composition of the phylotypes 
is mostly consistent across individuals, albeit there may be a large variability with 
regard to relative composition and diversity of the included microorganisms, 
intra-individually depending on anatomical site and inter-individually at the same 
anatomical location. In addition, there are inter-individual variations at the same 
anatomical site.
The gut microbiota is critical for the development of the gut mucosal immunity 
[11, 12], and it is also involved in the regulation of the hypothalamic-pituitary-
adrenal (HPA) axis [13], serotonergic neurotransmission [14], and signaling 
mechanisms affecting neuronal circuits involved in motor control and anxiety in 
mice [15]. This pathway has been named the gut-brain axis [16].
2. The gut-brain axis
The existence of the gut-brain axis is exemplified by irritable bowel syndrome 
(IBS) where more than half of the patients also suffer from mood disorders and for 
which antidepressants is one of the more common pharmaceutical treatments [17]. 
In IBS and other potential gut-brain axis disorders, cognitive alterations seem to 
be key features of the disorders [18]. These cognitive alterations might be induced 
by signal transduction from gut to the brain [18]. In addition, the existence is also 
shown by the effects of antibiotic exposure, which may lead to altered brain function 
such as anxiety, panic disorder, major depression, psychosis, and delirium which are 
usually described as side effects of antibiotic treatment [19]. Support for the latter 
comes also from studies in mice which have shown that an altered composition of 
the gut microbiota in adult mice, and an increased exploratory behavioral including 
hippocampal expression of Brain Derived Nerve growth Factor (BDNF) has been 
found after oral administration of non-absorbable antimicrobials [20], in contrast to 
intraperitoneal administration, which had no effect on behavior or BDNF levels.
Another area of evidence for the gut-brain-axis stems from dietary induction of 
changes in gut microbiota and linked psychopathological outcomes. For example, 
a high fat diet has been found associated with an altered microbial diversity and 
diminished synaptic plasticity [21, 22] but also increased vulnerability and anxiety-
like behavior in the mice [23]. In addition, a diet high in sucrose also led to an 
altered microbial diversity associated with impaired development of spatial bias for 
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long term memory, short term memory, and reversal trainings [24]. Another strong 
evidence for the gut-brain axis comes from a study in mice exposed to a microbiome 
depletion and/or transplantation paradigm where microbiota, in a first step, was 
isolated from donors who were provided with either in high fat diet or a controlled 
diet, and thereafter in a second step, transfused to mice who developed significant 
and selective disruptions in exploratory, cognitive, and also developed the stereo-
typical behavior following the high fat diet [25]. However, there are also evidence 
from studies where alcohol exposure, smoking habits, and disruptions in diurnal 
rhythm all have been shown to affect the microbiota composition.
There are also other evidence pointing to a reciprocal interaction from a study 
where a second generation antipsychotics, olanzapine, was exposed to rats and 
found to affect the composition of the microbiota, which also triggered an inflam-
matory response and weight gain [26, 27]. Furthermore, the exposure to antibiotics 
seemed to attenuate these physiological effects [28].
The microbiome has also been found to have been altered in various psychiatric 
conditions, or to affect its clinical expression, as well altered in rodent models for 
these disorders [29]. One example is major depressive disorder (MDD) where, 
for example, in germ-free mice (mice completely void of bacterial microbiota or 
derived molecules), there are both changes from comparable normal mice in the 
hypothalamic, pituitary, adrenal stress response, as well as altered levels of mono-
amines concentrations or their receptors [13–15, 20, 30]. Indirect evidence in MDD 
also comes from an increased serum antibody level to lipopolysaccharides that 
stems from Gram-negative enterobacteria, which are higher in MDD compared to 
controls [31], and which is associated with stress associated increased gut perme-
ability and bacterial translocation in animal models [32, 33]. In addition, depression 
also altered the gut microbiota in a mouse model, in which chronic depression and 
anxiety-like behaviors were induced by olfactory bulbectomy [34], suggesting a 
feedback loop between depressive states and dysbiosis.
Furthermore, a similar type of relation between dysbiosis and psychopathogen-
esis is found in schizophrenia [35, 36]. For example, elevated levels of serological 
markers of bacterial translocation have been found to be highly correlated with sys-
temic inflammatory markers in schizophrenia [37], and, cytokine levels in schizo-
phrenia are correlated with the severity of symptomatology [38]. From a genetic 
point of view, several of the strongest associations identified between genetic risk 
and schizophrenia stems from genes that are linked to immunological function  
[57, 58]. This is particularly interesting in view of the genetic association between 
AN and schizophrenia [39].
3. How is the effects in the gut-brain axis mediated?
The mechanism behind the gut brain axis may be multifaceted involving neural 
signal transduction in nervus vagus, neurotransmitters, immunological mecha-
nisms, and mechanisms related to metabolism and energy utilization [40]. One 
of the strongest links from a mechanistic point of view, stems from research on 
serotonin and the microbiota. Enterochromaffin (EC) cells provides approximately 
95% of the total body content of serotonin [41] of which the majority exists in 
plasma. Multiple levels of evidence links disturbances in the serotonergic system 
and several psychiatric disorder such as depression, anxiety, and borderline person-
ality disorder. For example, the metabolism of tryptophan, a precursor of sero-
tonin, is potentially regulated by the gut microbiota thereby enabling it to influence 
brain function [42]. Tryptophan is an essential amino acid derived from the diet 
[43], and tryptophan that is absorbed from the gut into the bloodstream passes the 
Anorexia and Bulimia Nervosa
4
blood-brain barrier to contribute to serotonin synthesis in situ [43]. The availability 
of tryptophan is strongly affected by the gut microbiota, and several studies have 
indicated that bacteria such as streptococcus, Escherichia, enterococcus species 
and Bifidobacterium infantis, and especially indigenous spore-forming bacteria may 
modulate serotonin levels by increasing plasma tryptophan [44]. An example of this 
is studies in germ free mice that have found that they exhibit an increased plasma 
tryptophan concentration [14, 15], which after post weaning colonization can be 
normalized [14]. The serotonergic neurotransmission may thereby be influenced 
by the availability of tryptophan for serotonin production [45]. There are studies 
have found that a depletion of tryptophan influences mood, anxiety and borderline 
personality traits, for example, in AN and bulimia nervosa [46–49].
There are also other evidences that link the gut microbiota with psychiatric con-
ditions such as MDD. For examples, a recent publication by Seng et al. [50] provides 
three additional levels of evidences: (a) that germ free mice lacks gut microbiota 
and display depression like features in forced swimming test compared to conven-
tionally raised healthy control mice; (b) that the gut microbiota composition of 
MDD patients differ from that of healthy controls; and (c) and that transplantation 
of MDD microbiota to germ free mice led to the development of depression like 
behaviors. In addition, Seng et al. found that mice that were harboring the micro-
biota from MDD patients primarily exhibited disturbances of microbiome genes 
and host metabolism which thereby suggests that the depression-like behavior was 
mediated through the host metabolism [50].
Another neurotransmitter that is produced by the microbiota and that may 
influence host behavior is gamma aminobutyric acid (GABA) which is the 
main inhibitory neurotransmitter in the CNS. GABA produced by the probiotic 
Lactobacillus rhamnosus was administered to mice and led to an alteration in the 
expression of GABA receptors in different CNS regions, associated with reduced 
anxiety and depression-like behaviors [51].
Another mechanism for interaction between the microbiome and the CNS is 
at the level of the blood-brain barrier (BBB). The vascular BBB is comprised of 
specialized brain endothelial cells acts as a regulatory interface between brain and 
blood that prevent the unrestricted transfer of molecules into the CNS. Disruption 
of the tight junctions of the BBB can expose the CNS, and has also been linked to 
CNS disorders [52]. A dysbiotic microbiome could possibly interact with the BBB in 
several ways: bacterial factors and immune-active molecules released from periph-
eral sites influenced by the microbiome can cross the BBB, alter BBB integrity or 
change BBB transport [53]. In germ-free mice, it has been shown that the BBB has 
increased permeability compared to pathogen-free mice with a normal gut flora. 
The increased permeability was associated with reduced expression of the tight 
junction proteins. Exposure of germ-free adult mice to a normal gut microbiota 
decreased BBB permeability and up-regulated the expression of tight junction pro-
teins [54]. Metabolic products such as short-chain fatty acids (SCFAs) are produced 
through the fermentation of dietary fibers by the gut microbiota [55] and can cross 
the BBB to affect brain function. A low production of SCFAs could lead to increased 
BBB permeability and SCFAs has been shown to be able to improve a dysfunctional 
BBB in germ-free mice [54]. Another example is that antibiotics are able to modify 
barrier integrity and alter behavior in mice [56] and alterations to the microbiome 
composition in mice in favor of, for example, probiotic bifidobacteria spp. through 
food supplement with prebiotics showed impact on neuroinflammation and 
were accompanied with changes in the expression of tight junction proteins [57]. 
Furthermore, leptin, a key hormone for the control of appetite and weight gain, is 
normally restricted by the BBB but has been shown in mice with a deficit in leptin 
transport to the brain to enhance the sense of food reward [58].
5Dysbiosis of the Microbiota in Anorexia Nervosa: Pathophysiological Implications
DOI: http://dx.doi.org/10.5772/intechopen.85253
4. Microbiota findings in AN studies
Dysbiosis has been proposed in AN and through the long periods of starvation 
associated with the core psychopathology of AN, a considerable adaptation in gut 
microbiota could occur in individuals with AN. A systematic review by Schwennsen 
et al. [59] found some evidence of dysbiosis in AN, such as the abundance of the gut 
microbiota in AN, which was described as either normal [60, 61], reduced  
[62] or altered in AN [63]. In addition, the diversity of the gut microbiota in AN was 
described as normal [61, 63], or reduced (alpha, i.e., within-sample diversity)  
[64] both in the acute stage and after weight restoration.
Common microbiota findings in the acute stages of AN were low levels of 
phylum Bacteroidetes [61, 64], while the phylum Firmicutes was increased in AN 
in three studies [61, 64, 65] however decreased in a fourth [63]. Furthermore, 
the genus Methanobrevibacter and specifically, the species M. smithii, has been 
found increased in AN patients in several studies [60, 61, 63, 65]. It is important 
to remember the presence or lack of a specific bacterial spp. identified by their 
16rRNA gene is not the same as the presences or lack of certain metabolic functions 
or microbiota steady-state dynamic. The state of knowledge of the microbiota in AN 
is in its infancy and more studies are needed.
4.1 The microbiota and relation to clinical symptoms in AN
This systematic review [59] identified two studies describing an association 
between the microbiota and clinical symptoms in AN. In one study, ClpB pro-
tein concentrations were significantly correlated with several subscales on the 
Eating Disorder Inventory-2 (EDI-2) for patients with eating disorders and the 
Montgomery-Åsberg Depression Rating Scale (MADRS) total score and specifically 
the anhedonia score for AN patients (p < 0.05) [66]. In another study, an associa-
tion between alpha diversity and depression and eating disorder psychopathology 
was found in AN [64]. Should further studies find further support for that the 
microbiota drives the symptoms of AN, this would strengthen targeting the micro-
biota as a primary level of treatment of AN.
5.  How is the gut-brain axis involved in AN? Breakdown of organic 
material in the gut and its exposure in plasma
A potential mechanism through which the microbiota indirectly influences the 
pathophysiology and symptoms of AN is through the breakdown of organic material 
in the gut and the transfer of metabolites into the blood stream. One of the microbi-
ota that has been described in AN is M. smithii, which is involved in the breakdown 
of polysaccharides from vegetable sources and the finding of this specific Archaeon 
could illustrate an adaptation to a typical diet rich in vegetables and fruits in persons 
with AN. In addition, methanogenic Archaea, such as M. smithii, have also been 
linked to constipation, a common complaint in patients with AN, which statins have 
been shown to alleviate by suppressing the growth of methanogens [65, 67–69]. The 
evidence of M. smithii in feces from constipated patients necessitate further investi-
gation of whether this finding in AN patients is only related to constipation or also 
related to AN psychopathology as a potential biomarker.
The gut microbiota is involved in both weight gain and weight loss as well as with 
energy extraction from the diet in both humans and animals [70, 71]. Differences 
in the composition of the gut microbiota between obese and lean individuals have 
been consistently described, potentially illustrating differences in energy extraction 
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efficiency between obese and lean individuals [72, 73], and specific gut dysbiosis 
could predispose to the drive toward negative energy balance in AN. With regard 
to the effect of weight gain on the fecal microbiota, Firmicutes has been found 
increased after weight restoration in two studies in AN [61, 64].
6. AN comorbid disorder as evidence of microbiota influence
Intestinal dysbiosis has previously been associated with psychological function 
and mental health including depression and anxiety, both of which are commonly 
comorbid with AN [40]. AN patients often present with comorbid anxiety (75% 
lifetime prevalence of anxiety disorder) [74] and depression (more than 34% 
lifetime prevalence of depression) [75, 76]. These findings provide further support 
for a role of dysbiosis in the pathophysiology of AN.
7. A leaking gut in AN?
During starvation, some of the gut bacteria will have insufficient nutrient supply 
for survival. Slowly growing bacteria or bacteria able to feed on the mucus lining the 
gut wall will survive for a longer period of time [77]. The competition between bacteria 
with different growth capacities to survive and proliferate in the gut has probably taken 
place for millions of years. Thus, it is reasonable to expect that various mechanisms for 
survival and proliferation have emerged among gut bacteria including the capacity to 
release of substances inhibiting food intake of the host. Alterations in gut permeability 
has been linked to a number of intestinal diseases, such as irritable bowel syndrome 
(IBS), inflammatory bowel disease (IBD), but also to extraintestinal disease as depres-
sion, anxiety and autism specter disorders [78, 79]. Increased gut permeability may 
also facilitate signal transduction from the gut to the brain via the vagus nerve and 
blood [80], possibly in synergy with interaction with increased BBB permeability. In 
addition, in animal and human studies, the experience of stress is also linked to an 
increase in permeability of the intestinal barrier. This increase in permeability seems to 
be mediated through, among other factors, hypothalamic hormones, especially corti-
cotropi-releasing hormone (CRH) [77]. Increased mucin degrading bacteria has been 
demonstrated in AN [81] indicating that decreased food intake induce overgrowth of 
bacteria able to feed on the mucus layer and thereby increase gut permeability.
An example of a possible biomarker species is the bacterium Akkermansia muciniph-
ila which is abundant in humans and rodents and has been inversely correlates with 
body weight and is associated with metabolic syndromes and auto-immune diseases 
[82]. A. municiphilia is a symbiotic bacterium of the mucus layer, can utilize mucin 
as its sole carbon, nitrogen, and energy source and is able to produce certain SCFAs 
[83, 84]. In mice, it has been shown that the abundance of A. muciniphila decreased in 
obese and type 2 diabetic mice and that administration of the bacterium increased the 
intestinal levels of endocannabinoids that control inflammation, the gut barrier, and 
gut peptide secretion [82]. In a single AN patient case story, it has been shown that one 
treatment with a fecal matter transplant from a healthy donor led to weight gain and an 
increase in A. municiphilia and SCFAs blood levels [85]. A. municiphilia is an example 
of a complex interaction where the bacterium simultaneously degrade the mucin for 
energy, but also at the same time induces higher mucus production from the host. 
This could in turn improve protection of the gut wall from interaction with harmful 
molecules from other gut bacteria and leakage into the blood.
Furthermore, in an activity based mouse model of AN Jésus et al. demonstrated 
increased permeability in the colon, that is, “gut leakiness”, in anorexic mice, 
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however the authors also found that the gut leakiness was more related to malnutri-
tion than exercise [86]. Although there may be conflicting studies [87], yet another 
study examining the role of exercise on gut permeability, found that exercise 
increases intestinal permeability measured with the lactulose and rhamnose dif-
ferential urinary excretion test [88].
Another support for a leaking gut wall in AN comes from a study by Breton et al. 
[66], who found an increase in ClpB protein concentrations in plasma in eating disorder 
patients compared to plasma of controls, and furthermore, that ClpB protein concen-
trations correlated positively with alpha-Melanocyte Stimulating Hormone-(alpha-
MSH)-reactive IgG for all patients with eating disorders. ClpB protein is produced by 
Enterobacteriae such as Escherichia coli and has been found as a conformational mimetic 
of alpha-MSH, which is thought to be involved in satiety and anxiety [89]. The study 
adds evidence to the potential role of ClpB protein produced by Enterobacteriae in the 
gut and its impact on the brain and psychopathology in eating disorders.
The potentially altered gut permeability in AN may underlie the low-grade 
inflammation and increased risk of autoimmune diseases found in eating disorders 
[90]. Moreover, starvation has a significant impact on the gut microbiota, and a 
diet based on animal products used for re-nutrition, may stimulate the growth of 
bacteria that trigger inflammation [91].
8. A model for the pathophysiology of AN
The initial reduction of food intake induces alterations in the gut microbiota. 
These alterations in gut microbiota induce increased gut permeability. Due to this 
Figure 1. 
The initial reduction of food intake induces alterations in the gut microbiota. These alterations in gut 
microbiota induce increased gut permeability. Due to this altered microbiota and increased gut and in addition, 
increased blood-brain barrier permeability, neurohormonal signals interfering with food intake are transferred 
to the brain, influencing brain functions, for example, cognition. This contributes in creating a vicious circle 
which subserves maintaining in the mechanisms associated with AN.
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altered microbiota and increased gut and in addition, increased blood-brain barrier 
permeability, neurohormonal signals interfering with food intake are transferred to 
the brain, influencing brain functions, for example, cognition. This contributes in 
creating a vicious circle which subserves in maintaining the mechanisms associated 
with AN (Figure 1).
9. Conclusions
There are a lot of evidence linking dysbiosis and inflammatory and psychiatric 
disorders and although there are only a few studies that have examined the micro-
biota in AN, several of these point to a dysbiosis also in AN. The effects of this 
dysbiosis is mediated through the gut-brain axis, and leakage through the gut and 
potentially also the BBB, provide pathways for neurohormonal signals to induce and 
maintain psychiatric disorders such as AN. The evidence in AN will need confir-
mation and further clarification in larger, randomized and controlled studies. We 
propose a model for disease development and maintenance in AN where a dysbiosis 
is a key component. Future studies will need to clarify the pathophysiology of AN.
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